• Editors
  • Scope
  • Current Issue
  • Archive
  • Instruction for Author
  • Principles and Policies of transparency
  • Policies of corrections and retractions
  • EndNote style


2013 (v.21 no.2)

The Journal of Korean Society for Clinical Pharmacology and Therapeutics

Korean Society for Clinical Pharmacology and Therapeutics
Semiannual
ISSN: 1225-5467

  • Pharmacokinetic Characteristics of Cefcapene Pivoxil Hydrochloride after Single Oral Administration in Healthy Korean Subjects

    Su-jin Rhee, Kwang-Hee Shin, Yu-Jung Cha, Jung-Ryul Kim, Dal-Seok Oh, Joo-Youn Cho, Kyung-Sang Yu, In-Jin Jang, Jae-Yong Chung, Kyoung Soo Lim

    J Korean Soc Clin Pharmacol Ther | v.21, no.2, pp.104-112, Dec, 2013

    Abstract

    Background: Cefcapene pivoxil hydrochloride (CFPN-PI) is an oral ester cephalosporin antibiotic with a
    broad spectrum. In this study, we investigated the pharmacokinetics (PK) and tolerability of CFPN-PI
    following single oral administration in healthy Korean subjects.
    Methods: An open?label, dose?escalation, parallel group study was conducted in 18 healthy male
    volunteers. A single dose of CFPN-PI was administered to 6 subjects in each treatment group of 100,
    150 and 200 mg. Serial blood and urine samples were collected up to 12 h and 24 h after dosing,
    respectively. Plasma and urine concentrations of cefcapene were measured by HPLC-UV. PK parameters
    were estimated using non-compartmental analysis. For the safety evaluation, adverse event monitoring,
    clinical laboratory tests and physical examination were performed throughout the study.
    Results: Median values of time to peak plasma concentration were observed around 1.5 to 2.0 h.
    Maximum plasma concentrations (Cmax) were 1.04 ± 0.22, 1.24 ± 0.46 and 1.56 ± 0.43 mg/L (mean ± SD),
    and area under the plasma concentration?time curve (AUCinf) were 2.94 ± 0.46, 3.97 ± 1.28 and 4.70 ±
    1.19 h*mg/L in 100, 150 and 200 mg dose groups, respectively. The differences of dose?normalized Cmax
    and AUCinf among three groups were not statistically significant. The fractions of drug excreted in urine
    unchanged were 31.5 % - 42.9 %. There were no serious adverse events or clinically significant
    abnormalities related to CFPN-PI.
    Conclusion: CFPN-PI was well tolerated with single oral administration and showed a linear PK
    property within 100 - 200 mg in healthy Korean male subjects.

    Keyword

    Cefcapene pivoxil hydrochloride, Pharmacokinetics, Tolerability, Korean, Healthy subjects